Safety and Effectiveness of the XEN45 Glaucoma Treatment System in Patients With Angle Closure Glaucoma
Study Details
Study Description
Brief Summary
This study will evaluate the safety and IOP-lowering effectiveness of XEN in patients with Angle Closure Glaucoma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: XEN45 Glaucoma Treatment System (hereafter referred to as XEN) XEN45 unilaterally implanted in the study eye |
Device: XEN45
XEN45 unilaterally implanted in the study eye
|
Outcome Measures
Primary Outcome Measures
- Percentage of patients achieving at least a 20% reduction from baseline Hour 0 IOP while on the same number or fewer IOP lowering medications [Baseline to Month 12]
IOP will be measured using a Goldmann applanation tonometer
Secondary Outcome Measures
- Change from baseline the number of concomitant IOP-lowering medications [Baseline to Month 12]
The number of concomitant IOP-lowering medications following implantation will be compared with the number prior to implantation.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of ACG defined as areas of iridotrabecular contact present in ≥ 2 quadrants and glaucomatous damage to optic disc and visual field, in the study eye
-
Study eye has healthy, free, and mobile conjunctiva in the target quadrant
Exclusion Criteria:
-
Uncontrolled systemic disease (eg, diabetes, hypertension)
-
Known history of bleeding disorder or prolonged bleeding after surgery or those on pharmacologic blood thinners other than aspirin (up to 100 mg/day)
-
History of dermatologic keloid formation
-
Open angle glaucoma, active acute angle closure attack, congenital glaucoma, juvenile glaucoma, secondary glaucoma in the study eye
-
History of following surgeries in the study eye:
-
incisional refractive surgery (eg, radial keratotomy), other than astigmatic keratotomy or limbal relaxing incisions
-
corneal graft including partial grafts such as Descemet's stripping endothelial keratoplasty and Descemet's membrane endothelial keratoplasty
-
previous laser or incisional intraocular surgery that might interfere with the outcome of this trial
-
Previous glaucoma shunt implantation in the target quadrant in the study eye
-
Active or history of chronic uveitis in the study eye
-
Unable to discontinue contact lens wear in the study eye during the study
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Marsden Eye Specialists Parramatta /ID# 232761 | Paramatta | New South Wales | Australia | 2150 |
2 | Melbourne Eye Specialists /ID# 232767 | Fitzroy | Victoria | Australia | VIC3065 |
3 | Eye Surgery Associates P/L ATF Eye Surgery Associates Unit Trust /ID# 232765 | Vermont South | Victoria | Australia | 3133 |
4 | Institut de loeil des Laurentides /ID# 232780 | Boisbriand | Quebec | Canada | J7H 0E8 |
5 | Ophthalmology Clinic Bellevue /ID# 232782 | Montreal | Quebec | Canada | H1V 1G5 |
6 | Prism Eye Institute /ID# 232917 | Mississauga | Canada | L5L 1W8 | |
7 | Seoul National University Hospital /ID# 233099 | Seoul | Korea, Republic of | 03080 | |
8 | Nuh Medical Centre /ID# 232905 | Singapore | Singapore | 119082 | |
9 | Tan Tock Seng Hospital /ID# 233014 | Singapore | Singapore | 308433 | |
10 | Taipei Veterans General Hospital /ID# 232948 | Taipei City | Taipei | Taiwan | 11217 |
11 | Buddhist Tzu Chi General Hospital /ID# 232664 | Hualien | Taiwan | 97002 | |
12 | Royal Surrey County Hospital /ID# 233028 | Guildford | England | United Kingdom | GU2 7XX |
13 | Manchester University NHS Foundation Trust /ID# 232808 | Manchester | Lancashire | United Kingdom | M13 9WL |
14 | Queen Victoria Hospital /ID# 232812 | East Grinstead | West Sussex | United Kingdom | RH19 3DZ |
15 | East Suffolk and North Essex NHS Foundation Trust /ID# 232804 | Colchester | United Kingdom | CO4 5JL | |
16 | NHS Lothian /ID# 233052 | Edinburgh | United Kingdom | EH3 9HE |
Sponsors and Collaborators
- Allergan
Investigators
- Study Director: ALLERGAN INC., Allergan
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 1924-701-007